Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.63 +1.6%	$1.71	$1.41 ▼ $5.01	$8.85M	1.22	23,237 shs	17,489 shs
ATRA Atara Biotherapeutics	$8.06 +2.3%	$7.57	$5.01 ▼ $18.71	$46.98M	0.19	123,167 shs	29,533 shs
HOWL Werewolf Therapeutics	$1.25	$1.09	$0.60 ▼ $4.18	$56.09M	0.65	441,445 shs	477,897 shs
NRXP NRx Pharmaceuticals	$3.22 +3.9%	$2.58	$1.10 ▼ $6.01	$53.60M	1.54	414,381 shs	278,116 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	+1.56%	-7.41%	-2.69%	-27.46%	-60.75%
ATRA Atara Biotherapeutics	+2.28%	+3.33%	+12.89%	+21.75%	-2.72%
HOWL Werewolf Therapeutics	0.00%	+3.31%	+8.70%	+21.36%	-52.11%
NRXP NRx Pharmaceuticals	+3.87%	-3.59%	+22.90%	+55.56%	+20.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	2.9388 of 5 stars	3.5	3.0	0.0	1.1	2.5	1.3
ATRA Atara Biotherapeutics	4.0314 of 5 stars	3.3	3.0	4.7	0.6	2.5	0.6
HOWL Werewolf Therapeutics	3.1202 of 5 stars	3.5	3.0	0.0	0.6	5.0	0.6
NRXP NRx Pharmaceuticals	1.9339 of 5 stars	3.6	1.0	0.0	2.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	853.85% Upside
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	120.22% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	566.67% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	785.09% Upside

Current Analyst Ratings Breakdown

Latest APRE, HOWL, NRXP, and ATRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
5/9/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $6.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
3/31/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/25/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	5.99	N/A	N/A	$3.55 per share	0.46
ATRA Atara Biotherapeutics	$128.94M	0.37	N/A	N/A	($16.89) per share	-0.48
HOWL Werewolf Therapeutics	$1.14M	49.07	N/A	N/A	$1.65 per share	0.76
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.37	N/A	N/A	N/A	-1,095.02%	-68.39%	-55.74%	8/11/2025 (Estimated)
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
HOWL Werewolf Therapeutics	-$70.51M	-$1.67	N/A	N/A	N/A	N/A	-89.37%	-54.87%	8/14/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)

Latest APRE, HOWL, NRXP, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/8/2025	Q1 2025	HOWL Werewolf Therapeutics	-$0.44	-$0.40	+$0.04	-$0.40	$0.30 million	N/A
3/25/2025	Q4 2024	APRE Aprea Therapeutics	-$0.69	-$0.49	+$0.20	-$0.49	$0.15 million	$0.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.90	5.90
ATRA Atara Biotherapeutics	N/A	0.57	0.57
HOWL Werewolf Therapeutics	0.46	8.09	8.09
NRXP NRx Pharmaceuticals	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
ATRA Atara Biotherapeutics	70.90%
HOWL Werewolf Therapeutics	64.84%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
ATRA Atara Biotherapeutics	4.00%
HOWL Werewolf Therapeutics	23.60%
NRXP NRx Pharmaceuticals	19.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.53 million	4.78 million	No Data
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
HOWL Werewolf Therapeutics	40	44.87 million	34.28 million	Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable

APRE, HOWL, NRXP, and ATRA Headlines

Recent News About These Companies

NRX Pharmaceuticals Inc News (NRXP) - Investing.com

June 24 at 7:24 PM | investing.com

IBN Initiates Coverage of NRx Pharmaceuticals Inc.

June 24 at 7:24 PM | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

June 23 at 8:03 AM | prnewswire.com

NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from D. Boral Capital

June 20, 2025 | marketbeat.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $28.50 Average Price Target from Brokerages

June 19, 2025 | americanbankingnews.com

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 17, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 16, 2025 | financial-news.co.uk

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. ...

June 16, 2025 | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

June 16, 2025 | prnewswire.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Buy" from Brokerages

June 16, 2025 | marketbeat.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 12, 2025 | prnewswire.com

NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

June 6, 2025 | financial-news.co.uk

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

June 6, 2025 | finance.yahoo.com

NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital

June 6, 2025 | marketbeat.com

NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

June 5, 2025 | financial-news.co.uk

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

June 5, 2025 | finance.yahoo.com

New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms

June 5, 2025 | usatoday.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

June 5, 2025 | prnewswire.com

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

May 29, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

May 28, 2025 | financial-news.co.uk

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network

May 28, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, HOWL, NRXP, and ATRA Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.62 +0.03 (+1.56%)

Closing price 06/24/2025 03:53 PM Eastern

Extended Trading

$1.65 +0.03 (+1.60%)

As of 06/24/2025 04:02 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Atara Biotherapeutics NASDAQ:ATRA

$8.06 +0.18 (+2.28%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$8.06 0.00 (0.00%)

As of 06/24/2025 04:04 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Werewolf Therapeutics NASDAQ:HOWL

$1.25 0.00 (0.00%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$1.23 -0.02 (-1.52%)

As of 04:05 AM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

NRx Pharmaceuticals NASDAQ:NRXP

$3.22 +0.12 (+3.87%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$3.37 +0.15 (+4.78%)

As of 04:22 AM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time